<DOC>
	<DOCNO>NCT00965341</DOCNO>
	<brief_summary>The goal clinical research study learn testosterone replacement therapy may affect fatigue male advance cancer low testosterone level .</brief_summary>
	<brief_title>Testosterone Replacement Fatigue Male Hypogonadic Advanced Cancer Patients</brief_title>
	<detailed_description>Background Study : Testosterone main sex hormone male . Cancer , cancer treatment cancer symptom cause level body drop normal . When testosterone take drug ( call `` testosterone replacement therapy '' ) , therapy design return testosterone level normal . This may help control symptom low testosterone level , may include fatigue . In addition fatigue , low testosterone level may also cause depression , loss sexual desire , loss appetite , and/or physical change effect strength , stamen ( long-lasting strength energy ) , energy level , body composition . In study , researcher also want learn testosterone therapy may affect symptom may occur . To measure effect , questionnaire test use . Study Drug Administration : If find eligible take part study , randomly assign ( flip coin ) 1 2 group . One group receive testosterone , group receive placebo . A placebo substance look like study drug active ingredient . There equal chance assign either group . Neither , study doctor , study staff know whether receive testosterone placebo Day 72 . However , need safety , study doctor staff able find one receiving . You receive testosterone placebo injection buttock muscle , every 15 day Day 72 ( +/- 3 day ) . This baseline ( +/- 3 day ) , Day 15 ( +/- 3 day ) , Day 29 ( +/- 3 day ) , Day 43 ( +/- 3 day ) , Day 57 ( +/- 3 day ) . As part routine blood test perform study visit , testosterone level measure . If testosterone level high , testosterone/placebo dose lower . If testosterone level low , testosterone/placebo dose raise . Baseline Visit : On Day 1 , series test perform . Your strength stamen measure hand-grip strength test , Get-Up-and-Go test 6-minute walk test . - For hand-grip strength test , grip device hand hard . You repeat test 3 time hand . - For Get-Up-and-Go test , time see long take get sit chair , walk 10 foot , turn around walk back chair , sit . - For 6-minute walk test , time walk 100-foot loop . You walk 50 foot turn walk back begin . You walk speed feel comfortable many time 6 minute . A muscle upper arm measure . This arm normally use writing . You weigh scale measure body composition . Body composition include measurement body fat , `` lean '' ( non-fat ) body weight , much water body . Blood ( 1-2 tablespoon ) draw research inflammation , proteins hormone . These test design help researcher learn testosterone affect inflammation and/or fatigue , increase level certain hormone may help increase muscle appetite . You give device call Actiwatch , wear like wristwatch . It measure physical activity . The research staff show use . You wear Day 29 study . You return Day 15 Day 29 study visit . Other Study Visits : On Days 15 , 29 , 43 , 57 72 ( +/- 3 day ) , follow test procedure perform : - Blood ( 1 tablespoon ) drawn routine test . - You complete questionnaire . - Your strength stamen , arm muscle , body composition measure . - A medical history physical exam perform Day 29 ( +/-3 day ) Day 72 ( +/3 day ) If questionnaire response show may emotional difficulty depression , provide name mental health provider case would like receive mental health screening . Length Study : You may remain study Day 72 . You take study early intolerable side effect occur , cancer get bad , fatigue get bad . Optional Open-Label Testosterone Dosing : At Day 72 visit , find receive testosterone placebo . Those participant receive testosterone give option keep receive testosterone ( off-study ) . Those participant receive placebo also give option receive testosterone ( off-study ) . This call `` Open-Label Testosterone Dosing . '' If choose receive testosterone off-study Day 72 , receive testosterone injection buttock muscle . This investigational study . Testosterone replacement therapy commercially available FDA approve use men HIV , treat low testosterone level fatigue . ( HIV virus affect immune system . ) At time , investigational use testosterone replacement therapy treat low testosterone level fatigue patient cancer . Up 126 patient take part multicenter study . Up 80 patient enrol M. D. Anderson Cancer Center .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Male patient advanced cancer ( metastatic locally recurrent ) bioavailable testosterone ( BT ) &lt; 70 ng/dL . 2 . Male patient fatigue present every day last two week Edmonton Symptom Assessment System ( ESAS ) fatigue score last 24 hour &gt; /= 4 0 10 scale ( 0 = fatigue 10 = bad possible fatigue ) . 3 . Male patient willing receive intramuscular injection every 2 week 18 year age old eligible study . 4 . Participants must willing blood sample draw screen and/or baseline every two week end treatment . 5 . Prostatic Specific Antigen ( PSA ) level must lower 4.0 ng/mL eligible study Digital Rectal Exam ( DRE ) must normal . 6 . Eastern Cooperative Oncology Group ( ECOG ) PS &lt; /= 3 participant must able stand without assistance ambulate . 7 . Hemoglobin ( Hgb ) &gt; /= 9 g/dL . If patient blood drawn hemoglobin level past 28 day , one do determine eligibility . Patients hemoglobin &lt; 9 g/dL refer treatment anemia . 1 . Patients determine incapable completing questionnaire due cognitive physical deficit ineligible study 2 . Abnormal Digital Rectal Exam ( DRE ) baseline history severe untreated benign prostatic hypertrophy ( BPH ) International Prostatic Symptom Score ( IPSS ) &gt; 19 . 3 . Patients history prostate cancer , history breast cancer adenocarcinoma unknown origin . 4 . A history untreated obstructive sleep apnea . 5 . Uncontrolled severe heart failure ( NYHA Class III IV ) , uncontrolled cardiac arrhythmia severe chronic obstructive pulmonary disease ( COPD ) require home oxygen . 6 . Patients evidence preexist hypopituitarism/hypogonadism include status post bilateral orchiectomy , replacement therapy mandate , ineligible study . 7 . Patients exhibit clinically diagnose severe dehydration ineligible . 8 . Patients history uncontrolled arrhythmia . 9 . Patients currently receive androgen therapy dehydroepiandrosterone ( DHEA ) 10 . Diabetics history frequent episode hypoglycemia uncontrolled diabetes mellitus ( DM ) define fast glucose 200 mg/dL HbA1c 8 % . 11 . Uncontrolled thyroid disease 12 . Hypercalcemia ( correct calcium &gt; 10.5 g/dL ) ; estimate glomerular filtration rate &lt; 60 mg/min use Modification Diet Renal Disease glomerular filtration rate ( MDRD GFR ) ; ALT &gt; 3x upper limit normal ( UNL ) 13 . Patients warfarin , cyclosporine , dong quai , eucalyptus , dicumarol , germander , Jin bu huan , kava , pennyroyal , chaparral , comfrey , phenprocoumon ineligible study . 14 . Unstable symptom could contribute fatigue severe pain ( score &gt; 6 ESAS ) severe depression ( define score 15 great Depression Subscale Hospital Anxiety Depression Scale [ HADS ] ) . These symptom resolve stable &gt; /= 2 week baseline inclusion study . 15 . Patients hematocrit ( Hct ) &gt; upper normal limit ( UNL ) exclude due possible polycythemia . If patient blood drawn hematocrit level past 28 day , one perform baseline determine eligibility . 16 . Patients know sensitivity sesame seed product .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Testosterone Replacement Therapy</keyword>
	<keyword>Depo-Testosterone</keyword>
	<keyword>Testosterone cypionate</keyword>
	<keyword>Testosterone enanthate</keyword>
	<keyword>Hypogonadic</keyword>
	<keyword>Functional Assessment Cancer Therapy-Fatigue subscale</keyword>
	<keyword>FACIT-F</keyword>
</DOC>